Scarica l'app Stockscreener
19.47
7.33%
-1.54
Dopo l'orario di chiusura:
19.47
Precedente Chiudi:
$21.01
Aprire:
$21.28
Volume 24 ore:
407.08K
Relative Volume:
1.44
Capitalizzazione di mercato:
$269.75M
Reddito:
-
Utile/perdita netta:
$-8.89M
Rapporto P/E:
-27.81
EPS:
-0.7
Flusso di cassa netto:
$-6.48M
1 W Prestazione:
-5.87%
1M Prestazione:
+143.38%
6M Prestazione:
+97.06%
1 anno Prestazione:
+65.84%
Intervallo 1D:
$18.54
$21.28
Intervallo di 1 settimana:
$18.54
$30.82
Portata 52W:
$7.78
$30.82
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Confronta GLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
19.47 | 291.08M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | Noble Capital Markets | Outperform |
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Canada
Insider Buying: Snehal Patel Acquires Additional Shares of Greenwich LifeSciences Inc (GLSI) - GuruFocus
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares - MarketBeat
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
FY2025 Earnings Estimate for GLSI Issued By HC Wainwright - MarketBeat
How (GLSI) Movements Inform Risk Allocation Models - Stock Traders Daily
New milestone in breast cancer prevention claimed by Greenwich - The Pharma Letter
Greenwich LifeSciences extends insider share lock-up to Sept 2026 By Investing.com - Investing.com Nigeria
Greenwich LifeSciences stock soars after extending insider lock-up By Investing.com - Investing.com South Africa
Greenwich LifeSciences stock soars after extending insider lock-up - Investing.com
What's Going On With Greenwich LifeSciences Stock Monday? - One News Page
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Greenwich LifeSciences Takes Flight As FLAMINGO 01 Breast Cancer Trial Progresses - Nasdaq
Why Did GLSI Stock Surge 25% Today? - Stocktwits
Greenwich LifeSciences extends lock-up of shares to September 2026 - marketscreener.com
Greenwich LifeSciences Extends Lock-Up Of Shares To September 2026 - TradingView — Track All Markets
Greenwich LifeSciences Extends Share Lock-Up to September For Directors, Officers - marketscreener.com
Greenwich LifeSciences extends insider share lock-up to Sept 2026 - Investing.com
Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026 - Quiver Quantitative
Biotech locks insiders out of selling stock for six years to back cancer trial - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Raised to “Hold” at Wall Street Zen - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Raised to "Hold" at Wall Street Zen - MarketBeat
What's Going On With Greenwich LifeSciences Friday? - Sahm
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy - Sahm
Greenwich LifeSciences provides updates on Phase III breast cancer trial By Investing.com - Investing.com Nigeria
Greenwich Life Sciences Provides Updates On Breast Cancer Study; Outlines Corporate Strategy - Nasdaq
Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters - TipRanks
Greenwich LifeSciences provides updates on Phase III breast cancer trial - Investing.com
Greenwich LifeSciences Provides Updates on Phase III FLAMINGO-01 Clinical Trial and Corporate Strategy - Quiver Quantitative
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $51,742.00 in Stock - Defense World
How strong is Greenwich LifeSciences Inc. stock revenue growth2025 Retail Activity & Fast Gaining Stock Strategy Reports - bolumsonucanavari.com
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Profit Target & Low Risk High Reward Trade Ideas - Улправда
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aug PreEarnings: Will Greenwich LifeSciences Inc. stock maintain momentum in 2025 - Улправда
Will Greenwich LifeSciences Inc. stock maintain momentum in 2025July 2025 Sector Moves & Capital Efficiency Focused Strategies - Улправда
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Is Greenwich LifeSciences Inc. stock positioned well for digital economyQuarterly Earnings Report & Technical Pattern Based Signals - Улправда
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 4,100 Shares of Stock - MarketBeat
Will Greenwich LifeSciences Inc. stock outperform growth indexes2025 Trading Volume Trends & Low Volatility Stock Recommendations - DonanımHaber
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2025 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - Улправда
Greenwich LifeSciences Stockholders Reelect Board and Auditor - TipRanks
Greenwich LifeSciences (GLSI) reports 2025 shareholder votes and auditor approval - Stock Titan
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences (GLSI) Stock: Soars on 80% Recurrence Reduction Breast Cancer Vaccine Shows Promise in Phase III Trial - parameter.io
Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? - Benzinga
Greenwich LifeSciences shares jump on early breast cancer trial readout - MSN
Why Is GLSI Stock Rising Today? - Asianet Newsable
Greenwich LifeSciences stock soars after promising cancer trial results By Investing.com - Investing.com Canada
Greenwich LifeSciences Reports 80% Reduction in Breast Cancer Recurrence in FLAMINGO-01 Clinical Trial's Non-HLA-A*02 Arm - Quiver Quantitative
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 - GlobeNewswire
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Greenwich Lifesciences Inc Azioni (GLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):